RedHill Biopharma Announces First Patient Dosed in U.S. Phase ...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
TEL AVIV, Israel and RALEIGH, N.C., Feb. 17, 2021 /PRNewswire-AsiaNet/ -- - The U.S. Phase 2/3 study with once-daily, orally-administered RHB-107 (upamostat) evaluates treatment of patients with symptomatic COVID-19 who do not require hospitalization - the vast majority of patients - RHB-107 is a novel serine protea...
Authors: LATEST ASIANET NEWS RELEASES